-
Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts
Monday, February 8, 2016 - 4:27pm | 753Read More...Biotech stocks are in the midst of an "epic" selloff, Evercore ISI Mark Schoenebaum told CNBC on Monday. Schoenebaum is known for his coverage of big pharma, including Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Inc (NASDAQ: BIIB), Pfizer (NYSE: PFE) and AbbVie Inc (NYSE: ABBV)....
-
Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says
Friday, July 24, 2015 - 9:12am | 257Read More...In a note to clients on Friday, Evercore ISI analyst Mark Schoenebaum commented that investors were expecting Biogen Inc (NASDAQ: BIIB) to report a "weak quarter" but its print actually came in "probably even worse" than expected. Biogen earned $4.22 per share in the second quarter, beating the $4....
-
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Thursday, July 23, 2015 - 4:01pm | 519Read More...In separate reports published Thursday, Evercore-ISI's Biotechnology analyst Mark Schoenebaum dissected Eli Lilly and Co (NYSE: LLY) and Bristol-Myers Squibb Co (NYSE: BMY)'s conference call following the release of their quarterly results. Eli Lilly: Eight Key Takeaways Here are Schoenebaum's...
-
Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger
Wednesday, July 22, 2015 - 2:19pm | 385Read More...In a new presentation, Evercore ISI analyst Mark Schoenebaum breaks down the recently announced Celgene Corporation (NASDAQ: CELG) buyout of Receptos Inc (NASDAQ: RCPT). The deal is valued at about $7.2 billion, and the $232/share price that Celgene is paying represents about a 12 percent premium...
-
Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call
Sunday, July 5, 2015 - 2:26pm | 189Read More...In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned that the Orkambi approval ROW of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is on track with the EMA approval expected later in 2015. According to the Evercore ISI report, "Royalties… Will move into low double...
-
AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors
Friday, July 3, 2015 - 10:21am | 395Read More...In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned the abstracts and companies he would be tracking during the upcoming AAIC. This could include aducanumab by Biogen Inc (NASDAQ: BIIB) and solanezumab by Eli Lilly and Co (NYSE: LLY). AAIC is scheduled between July...
-
With Bristol-Myers Trial Stopped Early, 'What's Next?'
Friday, April 17, 2015 - 11:23am | 179Read More...Bristol-Myers Squibb Co (NYSE: BMY) announced on Fridady that its Opdivo trial was stopped early after superior results. Mark Schoenebaum at Evercore ISI said that expectations "were high going into the interim analysis," but the announcement removes any risk, however small. With the...
-
Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key
Tuesday, February 3, 2015 - 3:13pm | 287Read More...Gilead Sciences, Inc. (NASDAQ: GILD), expected to post results after the bell Tuesday, remains a darling on Wall Street after fears of a price war for its Sovaldi hepatitis C treatment receded last month. Investors will be looking for the company's estimate of sales related to hepatitis C...
-
Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact
Tuesday, December 23, 2014 - 5:13pm | 265Read More...AbbVie Inc's (NYSE: ABBV) agreement to be the exclusive hepatitis C treatment supplier to pharmacy benefits manager Express Scripts Holding Company (NASDAQ: ESRX) affects up to about 160,000 people in the U.S. suffering from the disease, according to calculations an analyst offered...
-
ISI Says AstraZeneca Needs To 'Speak Up For Increased Bid'
Monday, May 19, 2014 - 2:49pm | 429Read More...ISI analyst Mark Schoenebaum says Pfizer's (NYSE: PFE) final offer is in AstraZeneca (NYSE: AZN) shareholders' hands, calling it "effectively a 'hostile' tender offer." Pfizer on Sunday announced a fourth and final proposal of $92.53, or £55 per share. The press release states, "This proposal...
-
Analysts Comment on Merck's Hep C Regiment Advances
Monday, November 4, 2013 - 11:39am | 252Read More...Several analysts commented on Merck's (NYSE: MRK)'s advances on Hepatitis C cure regiment. ISI analyst Mark Schoenebaum commented that Merck's oral regimen for hepatitis C genotype 1 may be the first "truly clinical competitive" regimen against Gilead. Schoenebaum noted that this one pill per day...
-
ISI Group Believes That Genzyme Corporation (GENZ) Could Jump to $80
Tuesday, July 27, 2010 - 7:43pm | 192Read More...Mark Schoenebaum of ISI Group said on CNBC's Fast Money that a rumor that Sanofi-Aventis SA (ADR) (NYSE: SNY) could buy Genzyme Corporation (NASDAQ: GENZ) makes a lot of sense. He explained that Genzyme (GENZ) is still run by its founding CEO. He is 66 years old, and the company has some...
-
ISI Group Is Bullish On AMLN, HGSI, GENZ And DNDN
Wednesday, July 14, 2010 - 7:13pm | 289Read More...Mark Schoenebaum of ISI Group said on CNBC's Fast Money that he is looking at biotech stocks that have a specific catalyst. He believes that Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is a stock to watch, and sees it over $20 by the end of the year. Amylin has a diabetes drug that should be...
-
Deutsche Bank Analyst Likes Genzyme (GENZ), Gilead (GILD) And Amgen (AMGN)
Friday, September 11, 2009 - 6:26pm | 210Read More...Deutsche Bank analyst Mark Schoenebaum thinks that Genzyme (NASDAQ: GENZ), Gilead (NASDAQ: GILD) And Amgen (NASDAQ: AMGN) are currently undervalued. He thinks that Genzyme (GENZ) is the most controversial stock in all of biotech. They were forced to temporarily halt production of its plant due to...
